SRNE - Scilex completes enrollment in late-stage SP-102 lumbosacral radicular pain study

Sorrento Therapeutics ([[SRNE]] -1.2%) company Scilex Holding has completed enrollment in late-stage trial of SP-102 for the treatment of lumbosacral radicular pain ((sciatica)).The trial has randomized 400 patients at 40 sites across 25 states in the U.S. with the primary endpoint of mean change in the Numeric Pain Rating Scale for leg pain.Secondary endpoints include other measures of pain at 4 and 12 weeks, such as back pain, time to repeat injection of SP-102, safety and function.SP-102 is a non-opioid injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular pain.The company expects to post top line data from the study in Q4 2021.Separately, Sorrento's partner Mabpharm received New Drug Application ((NDA)) approval for its infliximab biobetter antibody in China.

For further details see:

Scilex completes enrollment in late-stage SP-102 lumbosacral radicular pain study